地西他滨联合小剂量化疗治疗难治性白血病的疗效分析  

Curative Effect Observation on Decitabine Combined with Low-Dose Chemotherapy in Treatment of Refractory Leukemia

作　　者：马洪霞[1] 陈蕾[1] 焦雪丽[1] 董秀娟[1] 

机构地区：[1]郑州市第三人民医院血液科,河南郑州450000

出　　处：《中外医疗》2016年第4期127-128,173,共3页China & Foreign Medical Treatment

摘　　要：目的探讨地西他滨与小剂量化疗用于难治性白血病的治疗疗效。方法整群选取2013年4月—2014年4月在该院进行治疗的27例白血病患者为研究对象,采用回顾性分析法观察分析该组患者的临床资料,所选患者均采用地西他滨联合小剂量化疗进行临床治疗,包括静脉滴注15 mg·m-2·d-1到20mg·m-2·d-1的地西他滨(治疗时间为第1天到第3天)和2 mg高三尖杉酯碱(第1天到第8天)以及20mg阿克拉霉素(第1、3、5、7天),同时皮下注射25 mg阿糖胞苷q12h(第一天到第8天),观察分析该组患者的治疗效果(治疗的总有效率)和不良反应情况。结果经过化疗治疗,该组患者中完全缓解者18例,占从体的66.7%,部分缓解者4例,占总体的14.8%,无效者5例,占总体的18.5%,化疗治疗的总有效率为81.5%,采用地西他滨联合小剂量化疗治疗的不良反应主要是血液学毒性。结论采用地西他滨与小剂量化疗治疗难治性白血病的临床效果显著,治疗后不良反应主要为血液学毒性(较为常见),能够有效的改善患者的生活质量,具有临床推广的应用价值。Objective To discuss the treatment curative effect of decitabine combined with low-dose chemotherapy in treatment of refractory leukemia. Methods 27 case of leukemia patients treated in our hospital from April 2013 to April 2014 were selected as the research object, the clinical data of this group was retrospectively observed and analyzed, the selected patients were treated with decitabine combined with low-dose chemotherapy in clinic, including intravenous infusion of 15mg·m-2·d- to 20mg·m-2·d-1 decitabine（ the treatment time was from the first day to the third day）, 2mg homoharringtonine（ from the first day to the eighth day） and 20 mg aclacinomycin（ the first, third, fifth, seventh day） at the same time,they were given subcutaneous injection of 25 mg cytosine arabinoside q12h（from the first day to the eighth day）, the treatment effect（ the total treatment effective rate） and toxic and side effect conditions of this group were observed and analyzed. Results After chemotherapy and treatment, in this group, 18 cases were complete remission, accounting for 66.7% of the total, 4 cases were partial remission, accounting for 14.8% of the total, 5 cases were ineffective, accounting for18.5% of the total, the total effective rate of chemotherapy and treatment was 81.5%, the toxic and side effect of decitabine combined with low-dose chemotherapy and treatment mainly was hematological toxicity. Conclusion The application of decitabine combined with low-dose chemotherapy and treatment in treatment of refractory leukemia has an obvious clinical effect, the toxic and side effect after treatment mainly is hematologic toxicity（more common）, which can effectively improve the patient＇s quality of life, and it is worthy of promotion and application in clinic.

关 键 词：白血病 地西他滨 小剂量化疗 

分 类 号：R4[医药卫生—临床医学]